RELAPSED B-CELL NON-HODGKIN LYMPHOMA
Clinical trials for RELAPSED B-CELL NON-HODGKIN LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new RELAPSED B-CELL NON-HODGKIN LYMPHOMA trials appear
Sign up with your email to follow new studies for RELAPSED B-CELL NON-HODGKIN LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New combo therapy targets Hard-to-Treat lymphoma
Disease control Recruiting nowThis study is for adults with B-cell non-Hodgkin lymphoma that has come back or stopped responding to treatment. Researchers are testing a drug called loncastuximab tesirine combined with other anti-cancer drugs to find the safest dose and see if it shrinks tumors. About 200 part…
Matched conditions: RELAPSED B-CELL NON-HODGKIN LYMPHOMA
Phase: PHASE1 • Sponsor: ADC Therapeutics S.A. • Aim: Disease control
Last updated May 14, 2026 12:03 UTC
-
New immune combo tackles tough lymphoma
Disease control Recruiting nowThis study tests a new mix of three drugs (CD19 t-haNK, N-803, and rituximab) in 20 adults whose B-cell non-Hodgkin lymphoma has returned or not responded to at least two prior treatments. The goal is to see if this combination can shrink tumors and improve survival. Participants…
Matched conditions: RELAPSED B-CELL NON-HODGKIN LYMPHOMA
Phase: PHASE2 • Sponsor: ImmunityBio, Inc. • Aim: Disease control
Last updated May 14, 2026 12:02 UTC